ALZpath, Inc.
PrivateLast Round
Seed Round
Jul 14, 2026
Total Funding Raised
$1.9M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
ALZpath, Inc. operates in Healthcare & Life Sciences and is based in Carlsbad, California. Its latest recorded funding round was a Seed round in May 2024.
ALZpath, Inc. is a biotechnology company that develops diagnostic tools and solutions for Alzheimer's disease, centered around its proprietary pTau217 antibody for blood-based testing.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Precision Medicine
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ALZpath, Inc. Comparables
Compare ALZpath, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AgenT | 79% | |
| C2N Diagnostics | 77% | |
| Veravas | 77% |
For institutional investors. Book with your work email.
ALZpath, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jul 14, 2026 | ||||
| Seed | May 21, 2024 | ||||
| Grant | Jul 18, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ALZpath, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| StartUp Health | Grant, Seed, Seed Round |
| Stead Impact Ventures and Foundation | Grant, Seed, Seed Round |
| Alzheimer's Drug Discovery Foundation | Seed Round, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 14, 2026
Monthly visitors increased 136% MoM, reaching 2.9K.
- Aug 22, 2026
Monthly visitors increased 85% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 7, 2026
ALZpath Inc. partners with Quanterix under an expanded licensing agreement that broadens use of pTau217 antibody technology on the Simoa research platform in California on Oct 7th '26.
- licenses_technologyOct 7, 2026
On Oct 7th '26 in California, ALZpath Inc. expands its licensing agreement with Quanterix to broaden use of its proprietary pTau217 antibody technology across the Quanterix Simoa research portfolio.
For institutional investors. Book with your work email.
ALZpath, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ALZpath, Inc.'s valuation, stock price, and market status.
Is ALZpath, Inc. a public or private company?
ALZpath, Inc. is a private company.
What is the current stock price of ALZpath, Inc.?
ALZpath, Inc. is a private company, so its shares have no public market price. Caplight tracks ALZpath, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ALZpath, Inc. worth (valuation)?
Valuation information for ALZpath, Inc. is not publicly available.
Can I buy ALZpath, Inc. stock?
ALZpath, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ALZpath, Inc.'s last funding round?
ALZpath, Inc.'s most recent funding round was Seed Round on July 14, 2026.
Who are the main investors in ALZpath, Inc.?
Key investors in ALZpath, Inc. include Alzheimer's Drug Discovery Foundation.
Will ALZpath, Inc. IPO soon?
No public IPO plans have been announced for ALZpath, Inc..
How can I track ALZpath, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in ALZpath, Inc.'s shares on secondary markets.